Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Hangzhou's Sciwind Closes $70 Million Series C for Metabolic Therapies

publication date: Oct 12, 2021

Sciwind Biosciences, a Hangzhou biopharma focused on metabolic disease, closed a $70 million Series C funding. Sciwind will use the proceeds to advance clinical development of its three leading GLP-1 receptor agonist candidates for NASH and other metabolic conditions. Sciwind has developed multiple proprietary technologies, including oral peptide and inhaled protein therapeutics delivery platforms, which are the basis of its products. The financing round was co-led by IDG Capital, Loyal Valley Capital and LYFE Capital. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China